In order to confirm the underlying correlation of oncogenic function and RAPTOR‐dependent activation of mTORC1, we performed a combination of pharmacological and genetic approaches to assess the activity of total and phosphorylated mTORC1 activity in CRC. The gene discussed is RPTOR; the disease is colorectal carcinoma.